Related Experiment Videos
Chlorpromazine reduces fluid-loss in cholera
Lancet (London, England)
|February 24, 1979
Summary
Chlorpromazine significantly reduced cholera fluid loss in patients by 66%. This study investigated its effectiveness in treating severe cholera, showing a notable decrease in stool output and improved patient comfort.
Area of Science:
- Gastroenterology
- Pharmacology
- Infectious Diseases
Background:
- Cholera causes severe intestinal fluid loss due to cholera toxin-induced adenylate cyclase stimulation.
- Chlorpromazine demonstrated inhibitory effects on this pathway in animal models.
Purpose of the Study:
- To investigate the efficacy of chlorpromazine in reducing fluid loss in human cholera patients.
- To assess the impact of chlorpromazine on stool output and patient symptoms.
Main Methods:
- Eleven severe cholera patients were administered chlorpromazine (intramuscularly or orally) at doses of 1 mg/kg or 4 mg/kg.
- Stool output was measured over 32 hours post-treatment.
- A control group of untreated patients was observed concurrently.
Main Results:
- Chlorpromazine treatment resulted in a 66% reduction in stool output.
- This reduction was significantly greater than the 26% decrease observed in untreated patients.
- Patients reported decreased nausea and mild sedation, enhancing comfort without causing hypotension.
Conclusions:
- Chlorpromazine effectively reduces fluid loss in human cholera.
- The drug offers symptomatic relief, improving patient comfort during cholera treatment.
- Chlorpromazine is a safe and effective adjunct therapy for cholera management in well-hydrated patients.